GENETIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET ANALYSIS

Genetic Chronic Obstructive Pulmonary Disease (COPD) Market, By Drug Class (Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Steroids, Antibiotics and Others), By Route of Administration (Oral and Nasal), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

Published In : Jan 2023
Code : CMI5512
Pages :178
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Market: Key Developments

In May 2022, Alembic Pharmaceuticals Ltd, a pharmaceutical company, received final approval from the U.S. health regulator for its generic version of Arformoterol Tartrate inhalation solution indicated for long-term treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. The approval by the U.S. Food & Drug Administration (U.S. FDA) for the abbreviated new drug application (ANDA) for Arformoterol Tartrate inhalation solution is for strength of 15 mcg (base)/2 mL unit-dose vial.